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Purpose: The enzyme cholesterol 24S-hydroxylase (Cyp46A1) is responsible for the conversion of cholesterol to its more
polar metabolite 24S-hydroxycholesterol, thereby enabling the intracerebral elimination of cholesterol. An intronic single
nucleotide polymorphism in the gene CYP46A1 (IVS2 −150 T>C; rs754203) has recently been associated with primary
open angle glaucoma (POAG). This association, however, lacks confirmation in other studies. The purpose of the present
study was to investigate a hypothesized association between rs754203 and the presence of POAG in a Central European
population of Caucasian descent.
Methods: The present institutional study comprised a total of 581 unrelated subjects: 330 patients with POAG, and 251
control subjects. Main outcome measures are genotype distributions and allelic frequencies determined by polymerase
chain reaction.
Results: No significant differences in either genotype distribution or allelic frequencies were found between patients with
POAG and control subjects (p>0.05). The presence of the rs754203 T-allele was associated with a nonsignificant odds
ratio of 0.81 (95% CI: 0.63–1.04; p=0.11) for POAG.
Conclusions: Our data suggest that the rs754203 polymorphism itself is unlikely a genetic risk factor for POAG in
Caucasian individuals.
The glaucomas are the most frequent cause of irreversible
blindness worldwide [1]. They are defined as progressive
optic neuropathies with apoptotic retinal ganglion cell death
leading to cupping of the optic nerve with typical visual field
defects.  Although  much  effort  has  been  made,  the  exact
pathomechanisms are still elusive [2]. Noteworthy, a positive
family  history  for  glaucoma  is  known  to  increase  the
individual risk substantially, albeit most of glaucoma cases
are likely to be multifactorial and presumably polygenic with
a  combination  of  distinct  genetic  variants  exerting  small
effects [3-6].
Some debate has been evoked by reports that cholesterol
lowering statins may decrease the risk of developing and
progression of glaucoma [7-9]. As cholesterol can not cross
the blood-brain barrier in significant amounts it has to be
synthesized de novo in the central nervous system [10]. For
elimination of cholesterol from the central nervous system, it
has  to  be  converted  into  its  more  polar  metabolite  24S-
hydroxycholesterol,  which  is  catalyzed  by  the  enzyme
cholesterol 24S-hydroxylase (Cyp46A1) [11]. Cyp46A1 is a
member of the cytochrome P-450 family and has also been
detected in rodent and bovine retinal ganglion cells, indicating
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a  physiologic  role  in  the  cholesterol  metabolism  of  the
mammalian retina [12,13].
It can be speculated that an altered function of Cyp46A1
may  either  lead  to  increased  intracerebral  cholesterol
concentration or accumulation of 24S-hydroxycholesterol. In
a  rodent  glaucoma  model  hypercholesterolemia  has  been
shown to cause oxidative damage of the retina via induction
of nitric oxide synthase 2 [14]. Furthermore, in an in vitro
study  24S-hydroxycholesterol  has  been  found  to  possess
neurotoxic  properties  in  physiologic  concentration  range
[15]. Interestingly, in a recent study a positive association
between an intronic single nucleotide polymorphism (SNP) in
the gene of Cyp46A1 (IVS2 –150 T>C; rs754203) and POAG
was reported in a French population [16]. This association,
however, lacks confirmation in other studies.
Our  study  was  thus  set  to  investigate  a  hypothesized
association between rs754203 of CYP46A1 and POAG.
METHODS
In the present institutional, retrospective case-control study
we investigated a total of 581 unrelated Caucasian subjects
comprising  330  patients  with  POAG,  and  251  control
subjects. All participants were of Caucasian origin, living in
the  same  geographical  area  and  were  seen  at  the  local
Department of Ophthalmology, Medical University of Graz,
Austria. The study was approved by the Institutional Review
Board of the Medical University of Graz and followed the
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616principles of the Declaration of Helsinki. Prior to enrolment,
written informed consent was obtained from all participants.
All patients underwent slit lamp biomicroscopy, testing
for  best  corrected  visual  acuity,  Goldmann  applanation
tonometry, gonioscopy, and standard automated perimetry
(Interzeag  Octopus  500,  program  G2)  or  –  in  cases  of
profoundly decreased visual acuity – Goldmann perimetry. In
all patients photographs of the optic disc were taken. Patients
with a known diagnosis of Alzheimer disease were excluded
from the study.
POAG  was  defined  by  an  intraocular  pressure  (IOP)
before initiation of a pressure-lowering therapy of at least
21 mmHg, an open anterior chamber angle, optic disk changes
characteristic  for  glaucoma  (notching,  thinning  of  the
neuroretinal rim, or increased cup/disc ratio in relation to the
optic  disc  size),  visual  field  defects  characteristic  for
glaucoma (inferior or superior arcuate scotoma, nasal step, or
paracentral scotoma) and absence of conditions leading to
secondary  glaucoma.  POAG  patients  were  classified
according to their mean defect (MD) on standard automated
perimetry using an adapted classification of Hoddap, Parrish,
and Anderson [17].
The control group consisted of 251 unrelated patients
with no morphological or functional damage indicative for
primary or secondary open angle or angle closure glaucoma.
Control subjects were admitted to our department for cataract
surgery.  All  participants  were  Caucasians  from  the  same
geographic area (Southern Austria).
Genotype determination: Venous blood was collected in
5  ml  EDTA  tubes.  DNA  was  isolated  form  peripheral
lymphocytes using QIAamp DNA blood mini-kit (Qiagen,
Venlo, Netherlands) following the manufactures protocol and
stored at −20 °C. Genotype determination was performed
using  high-resolution  melting  curve  analysis  on  the
LightCycler®  480  PCR  system  (Roche  Diagnostics  AG,
Risch, Switzerland). The samples were amplified in duplicate
20 μl reactions using the Light Cycler 480 High Resolution
Melting Master kit (Roche Diagnostics, Wien, Austria) and
analyzed on a LC480 instrument I (Roche Diagnostics GmbH,
Mannheim, Germany). The final reaction mix contained 1×
Master Mix, 3 mM MgCl2, 4 μM forward and reverse primer
and 50 ng of genomic DNA. For PCR the following cycling
conditions  were  chosen:  one  cycle  of  95  °C  for  10  min
followed by 45 cycles of 95 °C for 10 s, 60 °C for 15 s, and
72 °C for 20 s. The amplicons were then denaturated at 95 °C
for 1 min, cooled down to 40 °C for 1 min, and then melted
from 65 °C to 95 °C with 25 signal acquisitions per degree.
To detect sequence variations the Gene Scanning Software
v1.5 (Roche Diagnostics GmbH) was used. Using the Auto
Group mode samples were automatically grouped because of
their melting curves.
Statistical analysis: Descriptive statistics were used to
calculate frequencies and percentages of discrete variables.
Continuous data are given as mean±standard deviation (SD).
Means were compared using Mann–Whitney test. Proportions
of groups were compared by the χ2 test. Odds ratio (OR) and
95% confidence interval (95%CI) were calculated by logistic
regression.  The  criterion  for  statistical  significance  was
p≤0.05.  Hardy–Weinberg  equilibrium  has  been  calculated
using HW Diagnostics-Version 1.beta (Fox Chase Cancer
Center, Philadelphia, PA). Statistical analysis was done using
the SPSS statistical package (SPSS, version 17.0, Chicago,
IL). Power calculation was done using PS Power and Sample
Size Calculation software version 2.1.30 [18].
RESULTS
Our study included 330 patients with POAG (196 female and
134 male), and 251 control subjects (126 female and 125
male). The mean age of patients with POAG was 73.5±10.0
years, and 74.2±7.2 years in control subjects, respectively. 59
(17.9%) patients had early (MD above −6dB), 87 (26.4%) had
moderate (MD between −6 and −12 dB), and 127 (38.5%) had
severe (MD below −12dB) defect.
No significant differences in either genotype distribution
or  allelic  frequencies  of  rs754203  were  found  between
patients with POAG and control subjects (Table 1). Presence
of the rs754203 C-allele was associated with a nonsignificant
odds ratio of 1.23 (95% CI: 0.96–1.58; p=0.11) for POAG.
Furthermore, no significant differences in either genotype
distribution or allelic frequencies of rs754203 were found
between patients with early, moderate or severe defect and
control subjects (Table 2).
The present study had a statistical power of 0.80 to detect
an odds ratio of 1.42 for the rs754203 C-allele in patients with
POAG.
The observed genotype distributions did not deviate from
those predicted by the Hardy–Weinberg equilibrium, and for
control subjects were similar to those reported for Caucasian
populations [19,20].
DISCUSSION
Conversion  of  cholesterol  to  24S-hydroxycholesterol,
catalyzed by Cyp46A1, is the critical step for the elimination
of cholesterol from the central nervous system [10]. Alteration
of this enzyme may therefore lead to a dysbalance of the
intracerebral  cholesterol/24S-hydroxycholesterol
homeostasis,  which  may  contribute  to  neurodegenerative
diseases like POAG [14,15]. Indeed, a positive association
between an intronic SNP in the gene CYP46A1 (CYP46A1
IVS2 –150 T>C; rs754203) and POAG has been reported
[16].
In  the  present  study  genotypes  of  the  rs754203
polymorphism were determined in 330 patients with POAG,
and  251  control  subjects.  Allelic  frequencies  as  well  as
genotype distributions did not significantly differ between
patients with POAG and control subjects. This finding is in
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control subjects in a French study, in which an OR of 1.26
(95% CI: 1.006–1.574; p<0.05) for the TT genotype was
reported [16]. The controversial results may be explained by
different  sample  sizes  or  varying  genotype  distributions
among different populations.
Interestingly,  previous  studies  linked  the  rs754203
polymorphism to late onset Alzheimer disease (LOAD), a
chronic neurodegenerative disease mostly of the elderly like
POAG [19-27]. The results of these studies, however, have
been controversial and the risk-bearing allele and genotype
has not been the same in the positive studies. Of the positive
studies, three studies linked the T-allele to an increased risk
for LOAD, while five studies suggested the C-allele as risk-
bearing allele [19-27].
Generally, intronic SNPs may affect RNA splicing (i.e.,
exon skipping, intron retention, or introduction of ectopic or
cryptic  splice  sites)  or  RNA  stability,  thereby  modifying
functionality  or  synthesis  rate  of  a  genes  product  [28].
Papassotiropoulos and coworkers [16,19] provided evidence
that  the  brain  β-amyloid  load  and  the  cerebrospinal  fluid
concentration of β-amyloid are increased in individuals with
the  rs754203  TT  genotype,  whereas  serum  as  well  as
cerebrospinal  fluid  levels  of  cholesterol  and  24S-
hydroxycholesterol  appeared  to  be  unaffected  by  the
rs754203  genotype.  Interestingly,  most  studies  reported
decreased levels of β-amyloid in the cerebrospinal fluid of
patients with LOAD and likewise, Yoneda and coworkers
[29,30] found decreased levels of β-amyloid in the vitreous
fluid  of  patients  with  glaucoma.  As  mentioned  above,  an
unambiguous genetic impact for rs754203 has not yet been
established indicating that it may be in linkage disequilibrium
with a causative locus.
In  conclusion,  in  the  present  study  no  statistically
significant difference in the genotype and allele distribution
of the rs754203 polymorphism was found between patients
with  POAG  and  control  subjects,  suggesting  that  this
polymorphism itself is unlikely a major risk-factor for POAG
in  a  Caucasian  population.  Further  studies  are  clearly
warranted to elucidate the functionality of this polymorphism
and its role in POAG.
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